ASX Announcement/Press Release | 23 October 2024
AdAlta Limited (ASX:1AD)

AdAlta appoints Consultant Chief Medical Officer - AdCella

This new engagements is part of AdAlta's plans to ensure AdCella is appropriately resourced to meet the anticipated near term uplift in clinical activity

Investment highlights

- AdAlta announces significant new additions to its AdCella leadership team
- Kevin Lynch MD, Consultant Chief Medical Officer (CMO)-AdCella, brings 25 years' experience in clinical development of haematology/oncology drugs, including in China, at Antengene, Celgene and Novartis
- This appointment will help support the anticipated near-term increase in clinical trial preparation and execution activity associated with AdCella's intended solid cancer cellular immunotherapy pipeline
- AdAlta is also appointing a Consultant Chief Medical Officer-AdSolis to support future AD-214 clinical trials

AdAlta Limited (ASX:1AD) ("AdAlta" or **"the Company")** is pleased to announce a significant addition to its AdCella leadership team. Kevin Lynch MB BS has been appointed as Consultant Chief Medical Officer (**"CMO"**)-AdCella. In this role he will help support the selection of in-licensed cellular immunotherapies and the design and execution of Phase I clinical trials by AdCella.

These clinical programs remain subject to the completion of financing and licensing arrangements.

AdAlta CEO and Managing Director, Tim Oldham said: "*We are delighted that Kevin has agreed to work with AdAlta as we build our clinical pipeline of cellular immunotherapies. Kevin brings deep expertise in clinical development in oncology, cell therapies and China to AdCella. This appointment is further demonstration that AdAlta has in place a well-credentialled team primed to deliver our AdCella strategy. We are also appointing a Consultant Chief Medical Officer-AdSolis who will bring decades or respiratory drug development, including in IPF, to AD-214 and our AdSolis subsidiary.*"

Consultant CMO-AdCella, Kevin Lynch MB BS, based in Australia with leading industry and China haematology/oncology experience

Dr Lynch has taken on the role of Consultant CMO-AdCella, as this AdAlta subsidiary continues to execute its "East to West" cellular immunotherapy strategy. AdCella aims to provide a pathway for innovative cell therapy products for solid cancers originating in Asia (where 60% of global clinical trials are taking place) to enter Western regulated markets, in the process bringing these transformative therapies to more patients. More than ten products are now in advanced due diligence pending licensing.

Dr Lynch is a highly experienced industry physician. His 30 years' experience span all stages of clinical development, regulatory and reimbursement approvals and post-registration medical activities. He has contributed to multiple transformational therapies in haematology/oncology at both early- to late-stage therapies, including imatinib, nilotinib, lenalidomide and pomalidomide. He has led high level regulatory interactions in Australia (including for cell therapies), China, South Korea, Singapore, Europe, and other

markets. Importantly, he has also provided senior input into multiple interactions with the US Food & Drug Administration (FDA).

Dr Lynch is Co-Founder of PopulusBio srl, a company focused on accelerating the development of meaningful therapies for people with debilitating diseases. His previous leadership roles include CMO at Antengene (a global oncology-focused biopharmaceutical company headquartered in China) and senior medical and clinical roles at Celgene and Novartis.

Consultant CMO-AdSolis also being appointed

To similarly advance preparation for further clinical studies of AD-214, a first-in-class molecule for fibrotic disease, the Company is also appointing a Consultant CMO-AdSolis to bring expertise in clinical development of therapeutics for respiratory and orphan diseases, including IPF.

Expanding our clinical pipeline

The appointments of these Consultant CMOs are the latest important steps towards expanding our clinical pipeline and executing our AdSolis (bringing a new approach to fibrotic disease) and AdCella (East to West cellular immunotherapies) strategies.

For a video summary of this release and opportunity to engage in a virtual discussion see: https://investorhub.adalta.com.au/link/vPn2ZP

This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries
The Capital Network
Julia Maguire
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

About AdAlta Limited

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body® technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body® technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta's lead i-body® enabled candidate is AD-214. At any time, 500,000 patients with lung fibrosis (IPF) face death from inability to breath, despite spending US$4.3 billion per year on pharmaceutical therapies. Fibrosis can affect all organ systems and around 45% of all western country deaths have a fibrotic disease component. AD-214 is taking a wholly new approach to treat IPF and other fibrotic diseases. AD-214 is a first in class (first to utilize this mode of action) molecule and has been shown to be safe in Phase I clinical studies and effective in multiple animal and laboratory models of fibrotic disease. In accord with its business model, AdAlta is creating a private, unlisted subsidiary called AdSolis to advance AD-214 into Phase II clinical trials through licensing and/or third party investment.

AdAlta believes that the i-body® technology is ideally suited for use in the creation of advanced cellular immunotherapies for cancer and that this field represents an opportunity to expand its clinical stage pipeline. It has entered a Memorandum of Understanding with SYNthesis BioVentures to investigate the formation of a jointly owned entity, to be called AdCella, that, once established, will provide innovative cellular immunotherapies originating in Asia with a pathway to western regulated markets via Australian clinical trials

and further enhancement with AdAlta's i-body® technology. It has appointed Cell Therapies Pty Ltd, Australia's leading manufacturer of cell and gene therapies, as AdCella's preferred manufacturer.

The Company is also entering collaborative partnerships to advance the development of its i-body® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body® platform by discovering and developing selected i-body® enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer; and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

For more information

 Join our InvestorHub

 Follow us on Twitter

 Follow us on LinkedIn

To learn more about AdAlta please click here: www.adalta.com.au